Earlier this week 23andMe appointed Andy Page as company president.
Andy brings to the job incredible business experience as well as a long history with 23andMe. He has watched the company closely since its founding and he has served on the board of directors since 2012. During that time Andy has seen 23andMe grow and articulate its business model. He is both very familiar with what 23andMe does and what it needs to do to continue to be a leader in the personal genomics sector.
He also jumps on board just as 23andMe has hit a period of rapid growth. As president of 23andMe Andy will oversee not just our business strategy, but also our operations. He will report to CEO and Co-Founder Anne Wojcicki, who will lead 23andMe’s research organization and continue to shape the long-term vision of the company.
After talking to employees earlier this week, Anne put Andy’s new position into perspective in a press release.
“Today’s announcement broadens the management team and reflects both our extraordinary growth and future ambitions,” Anne said this week. “Several months ago, we announced a goal of attracting one million customers by the end of 2013. I believe this goal is a stepping-stone for empowering even more individuals to take greater control of their health through personal genetics. Looking to 2014 and beyond, I see the need to focus on this vision for the future as well as our business strategy to ensure the company scales effectively.”
For his part, Andy sees a lot of potential for the business.
“This company can be transformative on a global scale, making personalized medicine and real-time research a reality,” Andy said. “The company has made significant progress in achieving its potential, and working with Anne and the rest of the 23andMe team I look forward to building a successful company that improves health care and advances the understanding of the human genome.”
Check out our press release here for more about Andy.